The investigator's long-term goal is to conduct Naloxone for Opioid Associated out of Hospital Cardiac Arrest (NOPACA), a randomized, double blind, controlled trial to determine the efficacy of naloxone vs. placebo in Opioid Associated out of Hospital Cardiac Arrest. The investigative team plan to randomize patients in OHCA to early naloxone administration vs. placebo after initial resuscitation and measure ROSC and survival. Challenges to designing NOPACA include uncertainty regarding: 1) the available pool of participants and number of EMS agencies needed to meet enrollment targets; 2) acceptability among patients, EMS and Emergency Medicine provider stakeholders, and 3) estimates of the study outcomes needed for sample size estimates. Toward obtaining the necessary information to design NOPACA, the investigators propose a pilot RCT of participants at high risk for OA-OHCA to verify a reasonable recruitment rate; treatment fidelity and acceptability; and adequate retention and measurement of outcomes at follow up. The investigators propose incorporating hypothesis testing of the feasibility outcomes to determine progression to a definitive trial.

开始日期2026-11-01

申办/合作机构

The University of California, San Francisco

NCT04650841

/ Not yet recruiting早期临床1期IIT

The Role of the Opioid System in Placebo Effects on Pain and Social Rejection

The current study probes the involvement of the opioid system in placebo effects on social pain, using the opioid antagonist naloxone. 60 participants who recently experienced an unwanted breakup will experience rejection-related stimuli and receive painful heat and pressure stimuli during fMRI scanning. Participants will be randomized to receive either a naloxone or saline nasal spray, and be informed that the spray is either saline, or an effective pain and negative emotion reducing agent.

开始日期2025-09-01

申办/合作机构

Trustees of Dartmouth College

NCT04975334

/ Enrolling by invitation临床2期IIT

Opioid Antagonism in Hypogonadotropic Hypogonadism

The goal of this study is to evaluate the effects of opioid antagonists on the hypothalamic-pituitary-gonadal axis in subjects with idiopathic hypogonadotropic hypogonadism (HH).

开始日期2025-05-15

申办/合作机构

The Schwartz Center for Compassionate Healthcare

100 项与盐酸纳洛酮相关的临床结果

登录后查看更多信息

100 项与盐酸纳洛酮相关的转化医学

登录后查看更多信息

100 项与盐酸纳洛酮相关的专利（医药）

登录后查看更多信息

30,069

项与盐酸纳洛酮相关的文献（医药）

2025-12-31·JOURNAL OF DERMATOLOGICAL TREATMENT

Hailey-Hailey disease successfully treated with naloxone: 2 case reports and Review of the literature on efficacy of opioid receptor antagonist in Hailey-Hailey disease patients

Review

作者: Sheng, Nan ; Wu, Jianbing ; Fang, Fang ; Duan, Zhimin ; Li, Chengrang ; Xu, Beilei ; Song, Hao ; Zheng, Junyou

BACKGROUND:

Hailey-Hailey disease (HHD), a genetic blistering disease, is caused by a mutation in a calcium transporter protein in the Golgi apparatus encoded by the ATP2C1 gene. Clinically, HHD is characterized by flaccid vesicles, blisters, erosions, fissures, and maceration mainly in intertriginous regions. Some patients remain refractory to conventional treatments. Previously, a series of reports have confirmed naltrexone as an effective option for those patients. However, in China, naltrexone is unavailable in some hospitals and unaffordable for some patients.

OBJECTIVE:

To confirm naloxone as a treatment option for HHD, and assess the efficacy rate and safety of naltrexone for patients with HHD.

METHODS:

Two patients with biopsy-proven HHD received naloxone (2 mg/d, via intravenous infusion). We followed up with the two patients, assessing the change of skin lesions and obtaining photographs. We searched the PubMed databases using the keywords 'Hailey-Hailey disease' or 'benign familial pemphigus', and 'naltrexone' or 'naloxone', and reviewed English publications of reports and analyzed the efficacy and safety of naltrexone.

RESULTS:

Two patients prescribed naloxone showed completely remission in two weeks without any adverse reactions. The total remission rate of naltrexone for HHD is approximately 80%, without severe adverse effects.

CONCLUSION:

Naltrexone is effective and safe in the treatment of HHD. Naloxone, an analog of naltrexone, can also effectively and safely treat HHD, potentially offering a new therapeutic option for patients with refractory HHD.

2025-07-01·AMERICAN JOURNAL OF EMERGENCY MEDICINE

Effect of opioid use disorder training on the attitudes of emergency medicine providers toward treatment of opioid use disorder

Article

作者: Shecter, Jonathan D ; Creighton, Ashley ; Wascak, Kimberly ; Kruse, Maxwell ; Murray, Brian Patrick

BACKGROUND:

Opioid Use Disorder (OUD) remains a significant public health concern in the United States, claiming a staggering number of lives annually. Medication Assisted Treatment (MAT) with buprenorphine has emerged as an effective intervention. However, its utilization remains low, especially in Emergency Departments (EDs), due in part to bias against addiction. This study evaluated the impact of a grant to increase OUD treatment in the ED from the Ohio Department of Health on bias among ED providers.

METHODS:

A longitudinal survey of emergency medicine providers was conducted before and after grant implementation to assess attitudes and prescribing behaviors.

RESULTS:

While the grant increased the number of providers prescribing MAT and naloxone, it did not significantly alter attitudes toward OUD treatment in the ED. Providers overwhelmingly recognized addiction as a medical condition deserving empathy, but views on the appropriateness of EDs for addiction treatment remained unchanged.

DISCUSSION:

Despite increased MAT prescriptions and naloxone distribution post-grant, the study suggests that broader cultural shifts are needed to integrate OUD treatment into ED practice fully. Efforts to destigmatize addiction and enhance provider education may be necessary to address underlying barriers to OUD treatment acceptance in the ED setting.

CONCLUSION:

This study highlights a critical gap between favorable attitudes toward OUD treatment and actual practice. Although education and grant incentives led to increased MAT prescribing, most providers were hesitant to initiate ED treatment. Challenges included perceived lack of training, time constraints, and lingering stigma surrounding addiction.

2025-06-01·DRUG AND ALCOHOL DEPENDENCE

People entering opioid substance use treatment have low rates of naloxone knowledge and possession

Article

作者: Black, Joshua C ; Ellis, Matthew S ; Ladka, Michael ; Monte, Andrew A ; Bredenberg, Erin ; Olsen, Heather ; Beekman, Kyle

BACKGROUND AND AIMS:

Deaths from opioid overdose are increasing in the United States (US) and distribution of the opioid antagonist naloxone is one key strategy to reduce mortality. In this cross-sectional survey, we assess the association of high-risk behaviors with possession of naloxone and knowledge of where to find it.

SETTING AND PARTICIPANTS:

5663 adults entering treatment for opioid use disorder at facilities throughout the US during the calendar year 2022 were surveyed.

ANALYSIS:

Using a logistic regression analysis, we compared self-reported ownership of naloxone and knowledge of where to find naloxone between individuals with different self-reported types and routes of opioid use, as well as those with a history of opioid overdose compared to those without.

FINDINGS:

Patients reporting fentanyl, heroin, and more than one type of opioid use had higher rates of naloxone possession than those reporting oxycodone use alone. Patients that reported injection drug use were more likely to possess (61 %) and know where to get (77 %) naloxone than those who did not inject drugs (44 % possessed and 58 % knew where to find naloxone, p < 0.001 for each comparison). Patients with a self-reported history of overdose were more likely to possess (59 %) and know where to get (77 %) naloxone than those without a history of overdose (42 % and 55 % respectively, p < 0.001 for each comparison).

CONCLUSIONS:

Gaps in naloxone possession and knowledge persist amongst patients entering treatment for opioid use disorder. Additional efforts to expand naloxone ownership are critical, including comprehensive educational programs, involvement of community-based organizations, and bystander training.

577

项与盐酸纳洛酮相关的新闻（医药）

2025-04-03

·GlobeNewswire-Health Care

Scienture Holdings, Inc. Issues Annual Letter to Shareholders

TAMPA, FL, April 03, 2025 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC. (NASDAQ: SCNX) a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced value to patients, physicians and caregivers through developing, bringing to market, and distributing novel specialty products to satisfy unmet market needs, is pleased to provide this annual update from its Chief Executive Officer, Surendra Ajjarapu, to its stockholders. This time last year, Scienture Holdings, Inc. (f.k.a. TRxADE Health, Inc.). was focused on health services IT assets and operations aimed at digitalizing the retail pharmacy experience. The primary operations were conducted through our wholly-owned subsidiary, Integra Pharma Solutions, LLC (“IPS”), which is a licensed pharmaceutical wholesaler and sells brand, generic and non-drug products to customers. We completed a sale of assets of our subsidiary TRXaDE Inc. to Micro Merchant Systems for $22.5 million in Q1 2024 and entered into a business combination with Scienture, Inc., a private branded and specialty pharmaceutical company, in an all-stock transaction valued at $103 million. This completed our transformation to a company focused on the development of a novel and innovative specialty product pipeline that provides comprehensive access and disease management solutions to patients, caregivers and the healthcare system. Today, we are a fully fitted branded and specialty pharmaceutical company through our wholly-owned Scienture, LLC subsidiary, with two (2) FDA approved commercial products to be launched in the second half of 2025. We received NDA approval for our first in-house product (ArbliTM) from the FDA and completed the strategic acquisition of a previously approved product (REZENOPY®) in March 2025. We have put together an accomplished commercial operations infrastructure and go to market capabilities, for bringing novel and innovative brand products to the market. Our R&D focus continues to be in place with our proprietary product pipeline in development by leveraging the 505b-2 NDA and BLA regulatory pathways, identifying and contracting with key technology partners and service providers for product development, manufacturing and clinical operations. We are also in the process of divesting our legacy subsidiaries related to healthcare IT and pharmaceutical wholesaler operations, to fully focus on the branded and specialty pharma segment. Scienture, LLC’s Story Scienture, LLC (previously known as Scienture, Inc.) was founded in June 2019 as a branded specialty pharmaceutical company with a mission to address critical gaps in patient care by challenging treatment paradigms, product safety and efficacy limitations, access and adherence hurdles, to deliver better patient solutions. It is committed to creating value by developing robust in-house platforms, acquiring or in-licensing differentiated products and nuanced commercialization, that address the needs of patients and caregivers. Central to Scienture, LLC’s vision is its well thought out and diverse product pipeline under development, which spans multiple therapeutic areas, indications, and market segments. Its agile commercialization model and capabilities in sales and marketing, ensures flexibility and broad reach in delivering impactful results. Executing and supporting this comprehensive vision are its founding and executive management teams and strategic partners, who have several years of industry experience and an impeccable track record of building and growing successful companies. Key Accomplishments to Date Through Scienture, LLC, we have demonstrated a strong track record of success in the achievement of several key and critical milestones associated with product development, regulatory filings and approvals, proprietary intellectual property filings, business development activities and structuring commercial operations and go to market infrastructure. Product Development No.ItemAccomplishments1.SCN-102 (ArbliTM) Completed all development activities and the filing and receiving final approval of the NDA from the FDAFinalized contract with strategic partner for the manufacturing and commercial supply of finished product.Filed three (3) Intellectual Property filings resulting in two (2) granted patents and one (1) patent application pending, which provide coverage till 2041 in the US market. The patents are eligible for listing in the FDA Orangebook. 2.SCN-104 Devised an innovative product strategy for an injectable pen formulation and device to treat migraine patientsSuccessfully completed all initial development activities and initial meeting with the FDA to finalize regulatory pathway for approval.Contracted with strategic partner based in US, Germany and Canada for all development and manufacturing activities, inclusive of pen device and cartridge filling.Continued product development, paving the way for targeting registration NDA batches for the product in 2025 and potential NDA filing in 2026.Filed Intellectual Property applications and work is ongoing to facilitate patent issuance. 3.SCN-106 Identified and initiated development activities on a value added biosimilar product in the CVS therapeutic area.Successfully contracted with a strategic partner with accomplished biologics development and manufacturing capabilities based in India for the development and manufacturing of the product.Completed successful FDA meetings for the determination of next steps of development and the full pathway to BLA approval.Continue to lead the execution of the product in 2025 and beyond to accomplish potential BLA filing in 2028. 4.SCN-107 Established an innovative product concept and development program for the non-opioid management of post-surgical pain, offering significant value to patients and caregivers.Structured a strategic collaboration with an EU-based partner for leveraging using novel, unique polymers and microsphere processing technologies.Completed successful FDA meetings for next steps of development and to formalize full development pathway for NDA filing and approval.Successfully filed Intellectual Property applications and work is ongoing to facilitate patent issuance. Business Development On March 4 of this year, Scienture, LLC executed a Definitive Agreement for the for the exclusive U.S. rights to commercially launch REZENOPY® (naloxone HCl) Nasal Spray 10mg, an opioid antagonist that was approved by the FDA on April 19, 2024. REZENOPY® is the most potent (highest strength) version of naloxone HCl available in the market. The product leverages the proven use of the active ingredient and form factor, with increased effectiveness against potent opioids. IQVIA data (MAT December 2024) indicates a total annual sales of $189 million, unit volume of $10.0 million (eaches) for Naloxone in the US market. Commercial Operations We have a robust and nimble commercial operations strategy and program to successfully launch Scienture, LLC’s commercial products, ArbliTM and REZENOPY®, in 2025 and other products in the future, as it continues to grow. Our experienced internal leadership and industry leading partners provide a strong platform across several key functional areas focused on driving market performance: Field Operations, Virtual Promotion, Digital Marketing and CRMBranding, Promotional Materials and Website ManagementPayor Contracting and Market AccessDistribution and Logistics Provider; GTN and O2C mgmt.Data Analytics and Market IntelligenceBroad Channel Access – Retail, Institutional and DTCGovernment Contracting and Access What’s Next Over the next 12 months, we will be focused on: Successful launches of Scienture, LLC’s two (2) commercial products to obtain meaningful market share and providing a platform for growth and profitability. IQVIA data (December 2024) indicates a combined total annual sales of $481 million for Losartan ($292 million) and Naloxone ($189 million) in the US market.Continue to execute seamlessly on all our product development initiatives and drive relentlessly through to regulatory filings and approvalContinue to leverage our deep industry networks to identify and close on potential revenue and margin opportunities through business development and licensing.Continue to empower and strategically enhance our workforce to deliver strong results Why Us and Why does it matter We are a holding company of a fully fitted specialty pharma company passionate about delivering innovative solutions across the healthcare landscape. Our unique model brings a confluence of talent, experience and a culture of success across product development, manufacturing, commercial operations and strategic partnerships. Even with the advent of ground-breaking technologies and treatment options, the pharmaceutical industry continues to face challenges in providing adequate care due to an aging population, rising healthcare expenditure, increasing prevalence of chronic diseases, stringent regulatory requirements and high development costs. Our value added approach to reinventing existing molecules through innovative technology provides elegant options to overcome these limitations. We seek to expand access and improve clinical outcomes through safe and efficacious products using targeted delivery mechanisms, which should enhance patient compliance and convenience and provide overall cost savings to the healthcare system. Scienture, LLC’s well thought out product pipeline continues to expand, starting with our near term and upcoming commercial launches. Scienture, LLC’s flexible and modular commercial model drives efficiency and synergies through all our operations while retaining its comprehensive go to market capabilities. Final Thoughts This year was about enhancing and building on the strong foundation that was laid for our company. The years ahead will involve focusing on the execution, growth and expansion of our differentiated capabilities to create value to patients, caregivers, healthcare system and our shareholders. Thank you for your continued support as we endeavor on this journey of bringing meaningful products and innovation to the specialty pharma landscape. About Scienture Holdings, Inc. SCIENTURE HOLDINGS, INC. (NASDAQ: “SCNX”), through its wholly owned subsidiaries, including Scienture, LLC, is a comprehensive pharmaceutical product company focused on providing enhanced value to patients, physicians and caregivers by offering novel specialty products to satisfy unmet market needs. Scienture, LLC is a branded, specialty pharmaceutical company consisting of a highly experienced team of industry professionals who are passionate about developing and bringing to market unique specialty products that provide enhanced value to patients and healthcare systems. The assets in development at Scienture, LLC are across therapeutics areas, indications and cater to different market segments and channels. For more information please visit and www.scienture.com. Forward-Looking Statements This press release contains certain statements that may be deemed to be “forward-looking statements” within the federal securities laws, including the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. Statements that are not historical are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements relate to future events or our future performance or future financial condition. These forward-looking statements are not historical facts, but rather are based on current expectations, estimates and projections about our company, our industry, our beliefs and our assumptions. Such forward-looking statements include, but are not limited to, statements regarding our or our management team’s expectations, hopes, beliefs, intentions or strategies regarding the future, including for the products we may launch and the success those products may have in the marketplace. In addition, any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. In some cases, you can identify forward-looking statements by the following words: “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “ongoing,” “plan,” “potential,” “predict,” “project,” “should,” “seek,” or the negative of these terms or other similar expressions, but the absence of these words does not mean that a statement is not forward-looking. Forward-looking statements are subject to a number of risks and uncertainties (some of which are beyond our control) that may cause actual results or performance to be materially different from those expressed or implied by such forward-looking statements. Accordingly, readers should not place undue reliance on any forward-looking statements. These risks include risks relating to agreements with third parties; our ability to raise funding in the future, as needed, and the terms of such funding, including potential dilution caused thereby; our ability to continue as a going concern; security interests under certain of our credit arrangements; our ability to maintain the listing of our common stock on the Nasdaq Capital Market; claims relating to alleged violations of intellectual property rights of others; the outcome of any current legal proceedings or future legal proceedings that may be instituted against us; unanticipated difficulties or expenditures relating to our business plan; and those risks detailed in our most recent Annual Report on Form 10-K and subsequent reports filed with the SEC. Forward-looking statements speak only as of the date they are made. Scienture Holdings, Inc. undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise that occur after that date, except as otherwise provided by law. For more information, please contact:IR@Scienture.com

并购上市批准申请上市引进/卖出

2025-04-02

·PRNewswire

Padagis Extends the Shelf-Life of Naloxone HCl Nasal Spray 4 mg to 36 Months

The three-year shelf-life extension improves naloxone access for communities and first responders who continue to fight the growing opioid epidemic ALLEGAN, Mich., April 2, 2025 /PRNewswire/ -- Padagis®, a leading generic manufacturer, announced today its over-the-counter (OTC) Naloxone HCl Nasal Spray 4 mg has now obtained an extended shelf-life of 36 months. Padagis' Naloxone HCl Nasal Spray is an original prescription-strength medication designed to rapidly reverse the effects of a life-threatening opioid overdose. The shelf-life extension is another example of Padagis' commitment to reducing healthcare costs and improving accessibility by delivering high-quality medicines through innovative approaches. "We believe every patient should have affordable access to the medication that best serves their needs especially when it comes to the opioid crisis," said Pamela Hoffman, President of Padagis. "Our commitment to expanding access is stronger than ever, which we believe strongly contributes to the recent trends indicating that opioid overdose deaths are declining. At just $29.99 for a two-dose pack, Padagis 4 mg naloxone nasal spray remains the most affordable OTC option available to consumers on Amazon, and now, with a longer shelf life, we're delivering even greater value to those who need it most." The three-year expiration will apply to newly manufactured medicine that is planned to be released by Padagis® as early as late second quarter of this year. Padagis encourages all customers and consumers to follow the expiration date printed on the product packaging. To learn more about Padagis and its OTC Naloxone nasal spray, visit: . To purchase Padagis Naloxone on Amazon, click here. For press inquiries, contact [email protected]. About Padagis Based in Allegan, Michigan, Padagis is dedicated to improving the well-being of patients and consumers by providing high quality, affordable, specialized healthcare products. The pharmaceutical company is a leading provider of extended topical medications and other specialty drugs in the United States and Israel. One of Padagis' flagship products is Naloxone, an over-the-counter nasal spray that acts as an antidote to opioid overdoses. Padagis is committed to making its Naloxone spray widely available to help put an end to the opioid crisis and save lives. Padagis employs over 1,300 people worldwide. Visit Padagis online at . SOURCE Padagis WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

2025-03-27

·PRNewswire

The SPOT Equips Spring Breakers with Life-Saving Tools Amid Rising Fentanyl Risks

FORT LAUDERDALE, Fla., March 27, 2025 /PRNewswire/ -- As thousands of spring breakers descend upon South Florida, The SPOT is once again taking to the beaches to help keep young people safe. With fentanyl-laced substances and drink spiking on the rise, The SPOT is distributing free naloxone (Narcan) and drink covers while educating visitors on overdose prevention and harm reduction strategies. Continue Reading The SPOT team during Spring Break outreach. Last year, The SPOT's team distributed over 9,000 doses of naloxone to beachgoers, empowering thousands of young people to act as first responders in overdose situations. This year, the initiative aims to reach even more spring breakers by increasing its distribution goal to 10,000 doses, ensuring critical resources are in the right hands before a crisis occurs. "Many spring breakers don't realize that substances they use could be laced with fentanyl," said Emelina Martinez, Safe Syringe Exchange Services Manager for The SPOT. "Our goal is to put even more naloxone in their hands this year because a single dose can mean the difference between life and death." In addition to naloxone, The SPOT will provide free drink covers to help prevent drink tampering at parties and bars. The team will also offer harm reduction education, equipping young people with the knowledge they need to stay safe and make informed decisions. While overdose deaths are declining, fentanyl-laced substances remain a serious threat. According to the Centers for Disease Control and Prevention, over 72,000 opioid-related overdose deaths occurred in the U.S. in 2023, with fentanyl as the primary driver. Access to harm reduction tools like naloxone remains more critical than ever. The SPOT is Broward County's only approved Syringe Services Program, operating as a mobile harm reduction and medical unit under Care Resource's Behavioral Health Department. Beyond Spring Break, The SPOT provides essential harm reduction supplies and basic medical care, connecting individuals to specialized services offered by Care Resource. Unlike other public health initiatives, The SPOT does not receive government funding for harm reduction services. The program relies on private donors and organizations, including Care Resource, United Way, Gilead Focus, The Fishman Family Foundation, and the late Dr. Peter Cinelli, to continue its life-saving work. "Our ability to provide these critical resources depend on community support," said Dr. Thomas Smith, Director of Behavioral Health Services at Care Resource and The SPOT. "Every donation helps us distribute more naloxone and harm reduction supplies to those who need them most." For more information about The SPOT, to request naloxone, or to report an overdose reversal, please visit thespotbroward.org, call 954-566-SPOT (7768), or email [email protected]. Weekly schedules are posted on Instagram (@thespotbroward) and Facebook (The SPOT Broward). About The SPOT: The SPOT is a mobile medical clinic and outreach program operated by Care Resource, providing no-cost harm reduction resources and medical services to communities in need. Through education, prevention, and support, The SPOT aims to make a positive impact on public health and safety. SOURCE Care Resource WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

100 项与盐酸纳洛酮相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D01340	盐酸纳洛酮	A06AH04 V03AB15	DB01183

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
急性淋巴细胞白血病	加拿大	Hikma Pharmaceuticals LLC	2025-02-01
阿片类药物过量	美国	Emergent Devices, Inc.初创企业	1971-04-13

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
疼痛	临床3期	比利时	Mundipharma Pharmaceuticals BV	2009-06-01
疼痛	临床3期	荷兰	Mundipharma Pharmaceuticals BV	2009-06-01
阿片滥用	临床前	美国	Consegna Pharma, Inc.初创企业	-

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT04473950 (CTgov)	临床1期	阿片相关性障碍 \| 慢性疼痛	10	Placebo+Naloxone Hydrochloride (Pain Group)	醖餘願簾壓遞築網獵簾(繭網夢餘糧繭憲遞蓋範) = 憲簾鹽觸餘積廠網觸醖積觸積膚簾蓋廠廠選製 (製齋鑰築網鬱壓膚網築, 1.17) 更多	-	2025-03-26
				Placebo+Naloxone Hydrochloride (No Pain Group)	醖餘願簾壓遞築網獵簾(繭網夢餘糧繭憲遞蓋範) = 獵鹹範選網觸網廠鏇夢積觸積膚簾蓋廠廠選製 (製齋鑰築網鬱壓膚網築, 0.92) 更多
NCT03176316 (FusionIleus, CTgov)	临床4期	肠阻塞	53	naloxone	廠願選夢膚選襯鬱顧襯 = 築簾廠遞鹽製鹽鑰鹹簾簾窪繭築醖構壓鏇窪壓 (獵鹽鹽鹹構觸鹹顧衊遞, 齋壓襯繭範積觸築餘餘 ~ 醖壓糧鑰遞鑰淵簾醖鑰) 更多	-	2024-07-01
NCT03149770 (CTgov)	临床2期	1型糖尿病 \| 低血糖	30	Naloxone (Naloxone)	憲選憲鏇遞艱構獵糧繭(夢餘獵鏇遞醖範蓋窪醖) = 積構鏇廠遞顧範願網廠蓋鹽顧廠壓鬱範醖壓壓 (鏇廠觸鬱淵構齋遞製餘, 12) 更多	-	2024-04-16
				placebo (Placebo)	憲選憲鏇遞艱構獵糧繭(夢餘獵鏇遞醖範蓋窪醖) = 襯觸艱淵鏇餘壓廠觸齋蓋鹽顧廠壓鬱範醖壓壓 (鏇廠觸鬱淵構齋遞製餘, 13) 更多
NCT04764630 (Pubmed \| JAMA Netw Open)	临床1期	阿片类药物过量	21	1 dose at 0, 2.5, 5, and 7.5 minutes	顧繭顧壓襯鏇鏇簾蓋願(簾鬱鹹觸醖醖觸憲鏇餘) = 襯選鏇齋築鑰繭觸範窪壓鏇築夢蓋鑰襯鹽鬱積 (齋簾膚遞糧糧選觸糧獵 )	-	2024-01-23
				2 doses at 0 and 2.5 minutes	顧繭顧壓襯鏇鏇簾蓋願(簾鬱鹹觸醖醖觸憲鏇餘) = 艱遞鑰衊鏇構襯鬱醖糧壓鏇築夢蓋鑰襯鹽鬱積 (齋簾膚遞糧糧選觸糧獵 )
NCT03570099 (Pubmed \| BMJ Open)	N/A	阿片类药物过量	-	Take-home naloxone distribution	蓋遞鬱廠構鬱鬱鏇淵淵(夢餘鏇簾網積鹹夢顧網) = 獵範憲繭鹽膚遞範築獵膚窪艱繭遞廠簾鹽蓋餘 (製艱遞簾積積獵衊遞鑰 )	-	2024-01-01
				intranasal naloxone (Control period (2013-2017))	蓋遞鬱廠構鬱鬱鏇淵淵(夢餘鏇簾網積鹹夢顧網) = 膚繭獵艱網襯膚範鹹膚膚窪艱繭遞廠簾鹽蓋餘 (製艱遞簾積積獵衊遞鑰 )
ADA2023	N/A	单纯自主神经功能衰竭	-	Intranasal naloxone (IN)	淵壓範顧簾衊壓製糧衊(衊壓糧餘餘鑰蓋鏇積餘) = 選獵鏇衊鹽觸艱製憲築遞顧鏇鹹鬱餘繭顧齋艱 (艱壓鹽製觸獵艱鏇鑰鹹 ) 更多	-	2023-06-20
				Placebo	淵壓範顧簾衊壓製糧衊(衊壓糧餘餘鑰蓋鏇積餘) = 觸鹹餘艱鏇顧鏇製淵壓遞顧鏇鹹鬱餘繭顧齋艱 (艱壓鹽製觸獵艱鏇鑰鹹 ) 更多
NCT04713709 (Corporate Publications) 人工标引	临床1期	阿片类药物过量	56	FMXIN001	選糧壓壓網壓廠鹽壓積(選襯簾鏇淵選糧鹽鑰範) = 製醖糧鹹網膚構窪範蓋餘鑰遞憲範淵製衊鬱遞 (網廠選衊築齋餘窪觸範 ) 更多	相似	2022-07-28
				NARCAN	選糧壓壓網壓廠鹽壓積(選襯簾鏇淵選糧鹽鑰範) = 窪廠夢餘築鑰繭糧構鹽餘鑰遞憲範淵製衊鬱遞 (網廠選衊築齋餘窪觸範 ) 更多
NCT04764630 (CTgov)	临床1期	-	21	naloxone (A. Four Naloxone Nasal Spray Doses (1 Every 2.5 Min))	壓選憲觸網蓋繭選鬱觸(襯繭鹹鹽獵遞獵觸積膚) = 壓夢鬱築製觸築齋製艱願鏇鬱艱壓製顧製壓糧 (窪憲壓鹹襯窪鑰獵繭製, 70) 更多	-	2022-07-15
				naloxone (C. Two Naloxone Nasal Spray Doses (1 Every 2.5 Min))	壓選憲觸網蓋繭選鬱觸(襯繭鹹鹽獵遞獵觸積膚) = 積範繭繭顧糧壓顧築範願鏇鬱艱壓製顧製壓糧 (窪憲壓鹹襯窪鑰獵繭製, 159) 更多
NCT02805972 (BEE, CTgov)	临床2期	肥胖	41	Placebo+Naloxone (Placebo, Then Naloxone)	衊淵鏇構壓構糧壓範鬱(簾蓋夢鹹構築壓願繭壓) = 範鏇積廠觸壓選醖淵齋製製膚積衊憲鑰顧願廠 (齋獵選繭膚獵憲鹽繭觸, 窪艱鹹築遞鹹鏇襯齋糧 ~ 糧廠齋鹽襯鹽艱醖襯膚) 更多	-	2021-11-03
				Placebo+Naloxone (Naloxone, Then Placebo)	衊淵鏇構壓構糧壓範鬱(簾蓋夢鹹構築壓願繭壓) = 襯鑰襯觸餘鹽構獵淵糧製製膚積衊憲鑰顧願廠 (齋獵選繭膚獵憲鹽繭觸, 壓襯構鏇淵選範鹹築蓋 ~ 齋選顧憲窪築鏇積範鏇) 更多
ASN2021	N/A	-	-	Baclofen	願範觸築製範壓膚衊憲(構膚繭鹽積糧繭膚淵築) = Neurotoxicity due to baclofen was suspected and urgent CVVH was instituted. By 12 hours, she started improving and by 48 hours, recovered completely. Her AKI as well as pancreatitis resolved. She eventually delivered a healthy baby girl. Mother and baby were discharged in stable condition. 壓齋構蓋願積顧窪簾範 (壓齋膚鑰餘膚鏇網鹽鹹 )	-	2021-10-27